Search filters

Filters

Clear All

Phase

  • 1
  • 7
  • 2
  • 2
  • 2
  • 15
  • 8
  • 3
  • 12

Found 15 Ovarian Cancer trials

A listing of Ovarian Cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Study of SynKIR-110 Autologous T cells Transduced with Mesothelin KIR-CAR in Subjects with Mesothelin-Expressing Advanced Ovarian Cancer Cholangiocarcinoma or Mesothelioma

18 years - 99 years
All genders
Phase 1
Interventional
This study involves research of an investigational therapy called SynKIR-110. SynKIR-110 is CAR T cell therapy. CAR T cell therapy is a type of treatment in which a patient’s T cells (white blood cells that are a part of the immune system) are changed in a laboratory so they can …
 Study to Evaluate Imaging Feasibility,  Safety and Diagnostic Performance Post Dosing of an Intraoperative Fluorescent Imaging Agent for Detection of Metastatic Lymph Nodes  Primary Tumors and Tumor Margins in Patients with Solid Tumors

Study to Evaluate Imaging Feasibility, Safety and Diagnostic Performance Post Dosing of an Intraoperative Fluorescent Imaging Agent for Detection of Metastatic Lymph Nodes Primary Tumors and Tumor Margins in Patients with Solid Tumors

18 years - 99 years
All genders
Phase 2
The purpose of this research study is to learn about the safety and effectiveness of using ONM 100 to obtain images of primary tumors and metastatic lymph nodes in patients with solid tumors undergoing routine surgery. Adults at least 18 years of age with a Biopsy-confirmed diagnosis of primary or …
 SOROCk- NRG-CC008 A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-Oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers

SOROCk- NRG-CC008 A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-Oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers

35 years - 50 years
Female
The main purpose of this study is to determine if two surgical procedures, the usual approach of removing the fallopian tubes and ovaries and the other approach of removing the fallopian tubes at this time with the plan to remove the ovaries at a later time, are no different for …

The OVAL Study: A Randomized Controlled Double-Arm Double-Blind Multi-Center Study of Ofranergene Obadenovec (VB-111) Combined with Paclitaxel vs. Paclitaxel Combined with Placebo for the Treatment of Recurrent Platinum-Resistant Ovarian Cancer

All genders
Phase 3
This double-blind, randomized controlled trial will examine the safety and tolerability of the combination of intravenous administration of VB-111 and paclitaxel compared to placebo and paclitaxel in patients with platinum resistant ovarian cancer.

A Phase 1 Open-Label Safety Pharmacokinetic and Preliminary Efficacy Study of STRO-002 An Anti-Folate Receptor alpha Antibody- Drug Conjugate (ADC) In Patients with Advanced Epithelial Ovarian Cancer (including Fallopian Tube or Primary Peritoneal Cancers) and Endometrial Cancers

All genders
Phase 1
This study has two parts: Part 1 (dose escalation) and Part 2 (dose expansion). The purpose of Part 1 is to determine: What effects, good and/or bad, STRO-002 has on subjects and their disease The highest dose of STRO-002 that can be safely given to subjects using a pre-defined starting …

A Phase 1 Open-Label Safety Pharmacokinetic and Preliminary Efficacy Study of STRO-002 an Anti-Folate Receptor alpha (FolR) Antibody Drug Conjugate (ADC) in Combination with Bevacizumab in Patients with Advanced Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers)

All genders
Phase 1
To evaluate the safety and tolerability of STRO-002/bevacizumab as a combination therapy. To further evaluate the toxicity and tolerability of STRO-002/bevacizumab in patients with Advanced Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) To characterize the PK of STRO-002 when administered with bevacizumab To assess the immunogenic potential …

A Phase II randomized double-blind study of the use of Rucaparib vs. placebo maintenance therapy in metastatic and recurrent endometrial cancer

All genders
Phase 2
This study plans to learn more about the use of Rucaparib maintenance therapy after completion of prior therapy for recurrent endometrial cancer. Rucaparib belongs to a drug class called PARP inhibitors. There are currently three drugs approved by the U.S. Food and Drug Administration (FDA) in the setting of ovarian …

UPCC 14920 A Phase 1b First-in-Human Dose Escalation and Expansion Study of XMT-1536 In Patients with Solid Tumors Likely to Express NaPi2b

All genders
Phase 1
First-in-human, Phase 1b/2 safety study of the antibody-drug conjugate (ADC) XMT-1536 administered as an IV infusion once every four weeks. Patients with tumor types likely to express NaPi2b were enrolled in dose escalation. Patients with platinum-resistant ovarian cancer and non-small cell lung cancer (adenocarcinoma subtype) are being enrolled in the …
 Multicenter  randomized  double-blind  parallel-group  add-on  superiority study to compare the efficacy and safety of ponesimod to placebo in subjects with active relapsing multiple sclerosis who are treated with dimethyl fumarate (Tecfidera )

Multicenter randomized double-blind parallel-group add-on superiority study to compare the efficacy and safety of ponesimod to placebo in subjects with active relapsing multiple sclerosis who are treated with dimethyl fumarate (Tecfidera )

All genders
Phase 3
This is a study to find out whether patients with active forms of Relapsing Multiple Sclerosis (RMS) who are treated with dimethyl fumarate (Tecfidera®) can be treated better by the addition of ponesimod (study drug). The purpose is also to evaluate the effect on disability and the safety of these …

A Pilot Single dose Open-Label Study of OTL38 Injection (OTL38) for Intra-Operative Imaging of Folate Receptor Positive Ovarian Cancer Comparing Camera Imaging Systems

All genders
This is a small scale investigational study to compare different fluorescent camera imaging systems against the current standard (Visionsense VS3 Iridium system) for patients with Ovarian cancer. The VS3 is and FDA approved device currently in phase 3 clinical trials at the University of Pennsylvania and other institutions in combination …
1 - 10 of 15